16490

Sigma-Aldrich

Bromopyruvic acid

≥98.0%

Synonym(s):
3-Bromo-2-oxopropionic acid
Linear Formula:
BrCH2COCOOH
CAS Number:
Molecular Weight:
166.96
Beilstein/REAXYS Number:
1746786
EC Number:
MDL number:
PubChem Substance ID:
NACRES:
NA.22
Pricing and availability is not currently available.

Quality Level

assay

≥98.0%

mp

77-82 °C

solubility

water: soluble 1 g/10 mL, clear to very slightly hazy, colorless

storage temp.

2-8°C

SMILES string

OC(=O)C(=O)CBr

InChI

1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)

InChI key

PRRZDZJYSJLDBS-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Bromopyruvic acid is an affinity label for cysteine residues†. It acts as cross-linker between nucleic acids and proteins. Kinetics of inactivation of pancreatic ribonuclease A by bromopyruvic acid has been investigated.
may contain traces of dibromopyruvic acid

Application

Bromopyruvic acid was used in the synthesis of imidazo1,2-apyridine-2-carboxylic acids.

Packaging

10, 50, 500 g in glass bottle

Other Notes

Affinity label for cysteine residues; Cross-linker between nucleic acids and proteins

Pictograms

Corrosion

Signal Word

Danger

Hazard Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

Hazard Codes

C

Risk Statement

34

Safety Statement

26-36/37/39-45

RIDADR

UN 3261 8 / PGII

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Alessio Bocedi et al.
Scientific reports, 8(1), 16050-16050 (2018-10-31)
Many proteins provided with disulfide bridges in the native state undergo amorphous irreversible aggregation when these bonds are not formed. Here we show that egg lysozyme displays a clever strategy to prevent this deleterious aggregation during the nascent phase when...
I Kameshita et al.
Journal of biochemistry, 86(5), 1251-1257 (1979-11-01)
Phosphoenolpyruvate carboxylase [EC 4.1.1.31] from Escherichia coli W was alkylated by incubation with bromopyruvate, substrate analog, leading to irreversible inactivation. The reaction followed pseudo-first-order kinetics. Mg2+, an essential cofactor for catalysis, enhanced the inactivation, and the enhancing effect increased as...
P M Alliel et al.
European journal of biochemistry, 105(2), 343-351 (1980-04-01)
We have reported in a previous communication a kinetic study showing bromopyruvate to behave as an active-site-directed reagent for flavocytochrome b2. It is shown here that inactivation is accompanied by incorporation of 3 mol reagent/subunit of oxidized intact enzyme and...
M H Wang et al.
The Biochemical journal, 320 ( Pt 1), 187-192 (1996-11-15)
The kinetic theory of substrate reaction during the modification of enzyme activity [Duggleby (1986) J. Theor. Biol. 123, 67-80; Wang and Tsou (1990) J. Theor. Biol. 142, 531-549] has been applied to a study of the inactivation kinetics of ribonuclease...
Ananda Herath et al.
Organic letters, 12(3), 412-415 (2009-12-30)
The first continuous flow synthesis of imidazo[1,2-a]pyridine-2-carboxylic acids directly from 2-aminopyridines and bromopyruvic acid has been developed, representing a significant advance over the corresponding in-flask method. The process was applied to the multistep synthesis of imidazo[1,2-a]pyridine-2-carboxamides, including a Mur ligase...
Articles
We presents an article about the Warburg effect, and how it is the enhanced conversion of glucose to lactate observed in tumor cells, even in the presence of normal levels of oxygen. Otto Heinrich Warburg demonstrated in 1924 that cancer cells show an increased dependence on glycolysis to meet their energy needs, regardless of whether they were well-oxygenated or not.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.